Scientific Affairs, EUROIMMUN US, 1 Bloomfield Avenue, Mountain Lakes, New Jersey 07046, USA.
Scientific Affairs, EUROIMMUN US, 1 Bloomfield Avenue, Mountain Lakes, New Jersey 07046, USA.
Clin Lab Med. 2020 Sep;40(3):331-339. doi: 10.1016/j.cll.2020.06.001. Epub 2020 Jul 2.
Development of new diagnostic tests in a commercial laboratory for neurologic disorders is challenging. Development occurs in a highly regulated environment. Relevant research infrastructure may not be readily available in-house and may require outsourcing with additional management and costs. Clinically characterized specimens for validation of biomarkers for esoteric diseases may be difficult to acquire, and market size may be difficult to predict. More common diseases with heterogeneous subsets may require better clinical definition. Absence of guidelines may delay health provider acceptance of novel testing. Regulatory agency approval and categorization of tests affects validation requirements and impacts market acceptance and reimbursement.
在商业实验室中开发新的神经疾病诊断测试具有挑战性。开发过程处于高度监管的环境中。相关的研究基础设施可能无法在内部轻易获得,并且可能需要额外的管理和成本进行外包。对于用于验证罕见疾病生物标志物的临床特征化标本可能难以获取,并且市场规模可能难以预测。具有异质亚组的更常见疾病可能需要更好的临床定义。缺乏指南可能会延迟医疗服务提供者对新型检测的接受。监管机构对测试的批准和分类会影响验证要求,并影响市场接受度和报销。